Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...
You are here: Home » Deals & Financings

Deals & Financings

Print

VC fundings, mergers and acquisitions, and other financing events...

Recent Articles

  SciClone Gains China Rights to Zensun’s Heart Failure Drug
May 17, 2013
SciClone Pharma in-licensed China rights to a heart failure drug from Zensun (Shanghai) Science & Technology Co. SciClone, which is headquartered in the US, usually markets western drugs in China. This time, the company has acquired a China-developed drug for China. The deal gives SciClone exclusive rights to market Neucardin™, a novel treatment for chronic heart failure, in China, Hong Kong and Macau. Zensun filed for approval of Neucardin with the CFDA last year. More details....

Stock Symbol: (NSDQ: SCLN)

Share this with colleagues:  

  RuiYi and Genor Enter License and Collaboration for Novel mAb
May 16, 2013
RuiYi Inc., a San Diego-Shanghai biotech startup, has signed an exclusive license and collaboration with Genor BioPharma to develop RuiYi’s lead molecule in China. The drug candidate, RYI-008, is a novel anti-IL-6 monoclonal antibody with potential to treat autoimmune diseases and cancer. Earlier this week, RuiYi announced that CMC Biologics would develop a cell line for RYI-008. More details....

Share this with colleagues:  

  Amgen's New JV Fulfills Promise to Emphasize China
May 15, 2013
To date, Amgen, the US biotech drug company, has not had a major presence in China. In February of this year, Amgen said it would use a combination of partnerships and M&A to increase its participation in the China market. The first of these relationships is the Amgen-Zhejiang Beta JV, announced last week, which will promote and distribute Amgen’s colon cancer Vectibix. More details....

Stock Symbol: (NSDQ: AMGN)

Share this with colleagues:  

  RuiYi Selects CMC Biologics to Develop Cell Line for mAb
May 14, 2013
RuiYi Inc., a San Diego-Shanghai pre-clinical stage pharma, has enlisted CMC Biologics to develop a cell line for RYI-008, a novel anti-IL-6 monoclonal antibody. CMC Biologics, which is located in Seattle and Copenhagen, will use its proprietary CHEF1® high-productivity expression plasmid for the cell line. RuiYi in-licensed global rights to RYI-008 last October from ArGEN-X, a Dutch company. The molecule is being developed as a treatment for cancer and inflammatory diseases. More details....

Share this with colleagues:  

  Vectura and KingYork Form China Respiratory JV
May 13, 2013
Vectura, a UK maker of inhaled therapies, has established a China JV with two partners: Tianjin KingYork Group Company, a specialist in corticosteroid products, and Zendex Bio Strategy, a Hong Kong private equity investor. The JV, which will be named Tianjin Kinnovata Pharmaceutical Company, will use Vectura’s Clickhaler and Duohaler dry powder inhaler technology platforms to bring treatments for asthma and chronic obstructive pulmonary disease (COPD) to China and the larger Asian region. More details....

Stock Symbol: (LSE: VEC)

Share this with colleagues:  

  ScinoPharm and Coland to Develop Oncology Drugs for China
May 10, 2013
ScinoPharm Taiwan and Coland Holdings have formed an alliance to bring generic oncology drugs to mainland China. The alliance has selected several of ScinoPharm’s APIs for development as injectible treatments. A third party will develop and manufacture the products, which will be co-marketed by Coland and ScinoPharm. Although Coland is listed in Taiwan and headquartered in Hong Kong, its operations, including a sales force, are in China. More details....

Stock Symbols: (TSE: 1789) (TSE: 4144)

Share this with colleagues:  

  Hutchison Chi-Med in Partner Talks for Cancer Drug
May 9, 2013
Hutchison Chi-Med expects to license global rights to fruqintinib, one of its novel small-cell cancer drugs, before year-end, according to CEO Christian Hogg. The company has been in due diligence discussions with potential partners, he added. Because the drug is a promising treatment for solid tumors, Chi-Med will conduct simultaneous clinical trials against several types of cancer, and the company wants a partner to help shoulder the financial burden. More details....

Stock Symbol: (AIM: HCM)

Share this with colleagues:  

  Zhejiang Beta Pharma Forms JV with Amgen
May 9, 2013
Zhejiang Beta Pharma and Amgen will form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in China. Vectibix is a treatment for colorectal cancer. In addition to being experienced with targeted therapies, Zhejiang Beta also has a well-established China oncology sales network. The JV will be 51% owned by Zhejiang Beta, with Amgen holding the remainder. More details....

Stock Symbol: (NSDQ: AMGN)

Share this with colleagues:  

  Zhejiang Huahai and Oncobiologics Sign Biosimilar Pact
May 8, 2013
Zhejiang Huahai Pharma has joined with Oncobiologics, a New Jersey biologics startup, to form a partnership that will develop, manufacture and promote biosimilars. Huahai will have exclusive rights to make and market four Oncobiologics-developed biosimilars in China. The two companies will also sign a co-development and commercialization agreement to bring the four products -- generic versions of Humira, Rituxan, Avastin and Herceptin -- to 30 developed countries. More details....

Stock Symbol: (SHA: 600521)

Share this with colleagues:  

  Leadman to Distribute IDS’s Diagnostic Products in China
May 7, 2013
Beijing Leadman Biochemistry Technology Co. will be the exclusive distributor in China for Immunodiagnostic Systems Holdings’ IDS-iSYS analyzer and assays. Headquartered in Great Britain, IDS considers itself a world leader in bone, cartilage and growth diagnostic tests. In addition, IDS and Leadman agreed to convert more than 50 of Leadman's proprietary immunoassays for use on the IDS-iSYS instrument. More details....

Stock Symbols: (SHE: 300289) (AIM: IDH)

Share this with colleagues:  

 
more articles >>
Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2013
  May 29-30, 2013
Beijing, China

>>More events...
Partner Events

China Medical Affairs Summit
  June 18-19, 2013
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners